Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP05 - Mesothelioma, Thymoma and Other Thoracic Malignancies
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
-
+
FP05.02 - An Early Detection and Prognostic Blood Biomarkers Signature for Malignant Pleural Mesothelioma Based on Targeted Proteomics
00:00 - 00:00 | Presenter: Ferdinando Cerciello
- Abstract
Loading...
-
+
P03 - Early Stage/Localized Disease - Clinical Trials in Progress
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease
-
+
P03.04 - Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations
00:00 - 00:00 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.13 - Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
00:00 - 00:00 | Presenter: Parthib Das
- Abstract
Loading...
-
+
P21 - Locoregional and Oligometastatic Disease - Treatment of Locally Advanced NSCLC
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P21.02 - Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
00:00 - 00:00 | Presenter: Sandip H Patel
- Abstract
Loading...
-
+
P40 - Risk Reduction and Tobacco Control
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Risk Reduction and Tobacco Control
-
+
P40.03 - Report on a Phytochemical-rich Dietary Intervention Trial to Prevent Lung Cancer: Implementation in a High-Risk Lung Screening Clinic
00:00 - 00:00 | Presenter: Marisa Bittoni
- Abstract
Loading...
-
+
P47 - Small Cell Lung Cancer/NET - Biology / Translational
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/NET
-
+
P47.10 - Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung
00:00 - 00:00 | Presenter: Walter Wang
- Abstract
Loading...
-
+
P48 - Small Cell Lung Cancer/NET - Chemo - IO
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/NET
-
+
P48.19 - Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center
00:00 - 00:00 | Presenter: Sandip H Patel
- Abstract
Loading...
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P75.03 - KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC
00:00 - 00:00 | Presenter: Suman Rao
- Abstract
Loading... -
+
P75.12 - Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy
00:00 - 00:00 | Presenter: Nitya Surya
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P78.05 - Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome
00:00 - 00:00 | Presenter: Cameron Champion Wood
- Abstract
Loading...
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.01 - TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezolizumab with Chemoradiation (AFT-16)
00:00 - 00:00 | Presenter: Woo Yul Byun
- Abstract
Loading... -
+
P79.04 - A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.
00:00 - 00:00 | Presenter: Dwight H Owen
- Abstract
Loading...